Cargando…

Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model

BACKGROUND AND AIM: Toxocara vitulorum is a bovine intestinal nematode. Immune pictures following infection are conflicting and stopping anthelmintic albendazole treatment recording reversed liver abnormalities. The purpose of this work was to evaluate the therapeutic potential of bone marrow mesenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Abo-Aziza, Faten A. M., Zaki, Abdel Kader A., Alajaji, Ahmed I., Al barrak, Saleh M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Veterinary World 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994112/
https://www.ncbi.nlm.nih.gov/pubmed/33776300
http://dx.doi.org/10.14202/vetworld.2021.347-363
_version_ 1783669696166363136
author Abo-Aziza, Faten A. M.
Zaki, Abdel Kader A.
Alajaji, Ahmed I.
Al barrak, Saleh M.
author_facet Abo-Aziza, Faten A. M.
Zaki, Abdel Kader A.
Alajaji, Ahmed I.
Al barrak, Saleh M.
author_sort Abo-Aziza, Faten A. M.
collection PubMed
description BACKGROUND AND AIM: Toxocara vitulorum is a bovine intestinal nematode. Immune pictures following infection are conflicting and stopping anthelmintic albendazole treatment recording reversed liver abnormalities. The purpose of this work was to evaluate the therapeutic potential of bone marrow mesenchymal stem cells (BMMSCs) therapy, subsequent to albendazole administration in rats infected with T. vitulorum. MATERIALS AND METHODS: The ultrasonographic and histopathological examinations as well as serum liver enzymes activity and the kinetics of recovery were investigated. The correlation of cell-mediated and humoral immune pictures was assessed by assaying immunoglobulins, splenocytes viability, phagocytic index, and Th1/Th2 cytokines. RESULTS: The cultured BMMSCs counting were 4.21×10(4) cells/cm(2) with 96.03% viability. Flow-cytometric analysis indicated positive CD90 (82%), CD105 (79%) and negative CD34 (0.37%), CD45 (0.42%), attesting to the suitability of the isolated BMMSCs for use in therapy. Transplantation of BMMSCs after albendazole administration significantly reduced the release of liver enzymes (p<0.05) indicating liver cellularity improvement. The ultrasonographic, macroscopic, and histopathological findings confirmed the biochemical results. Significant elevation in the levels of tumor necrosis factor (TNF)-α and interferon (INF)-γ with a decline in interleukin (IL)-4 was observed in the untreated model (p<0.05). However, albendazole treatment followed by BMMSCs therapy significantly lowered the release of TNF-α and INF-γ, associated with significant production of IL-4 and IL-10 (p<0.05). CONCLUSION: The final results indicated that the liver functions, histopathological findings, and immune parameters were aggravated after experimental T. vitulorum infection. Albendazole treatment followed by BMMSCs therapy was found to assist in regeneration of injured hepatic tissue. Besides, it appeared to modulate host defensive immune responses against T. vitulorum antigens. This work could define more clearly the events that manipulate the host immune, histopathological, and biochemical responses to minimize obstacles in using stem cell therapy in animal toxocariosis.
format Online
Article
Text
id pubmed-7994112
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Veterinary World
record_format MEDLINE/PubMed
spelling pubmed-79941122021-03-27 Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model Abo-Aziza, Faten A. M. Zaki, Abdel Kader A. Alajaji, Ahmed I. Al barrak, Saleh M. Vet World Research Article BACKGROUND AND AIM: Toxocara vitulorum is a bovine intestinal nematode. Immune pictures following infection are conflicting and stopping anthelmintic albendazole treatment recording reversed liver abnormalities. The purpose of this work was to evaluate the therapeutic potential of bone marrow mesenchymal stem cells (BMMSCs) therapy, subsequent to albendazole administration in rats infected with T. vitulorum. MATERIALS AND METHODS: The ultrasonographic and histopathological examinations as well as serum liver enzymes activity and the kinetics of recovery were investigated. The correlation of cell-mediated and humoral immune pictures was assessed by assaying immunoglobulins, splenocytes viability, phagocytic index, and Th1/Th2 cytokines. RESULTS: The cultured BMMSCs counting were 4.21×10(4) cells/cm(2) with 96.03% viability. Flow-cytometric analysis indicated positive CD90 (82%), CD105 (79%) and negative CD34 (0.37%), CD45 (0.42%), attesting to the suitability of the isolated BMMSCs for use in therapy. Transplantation of BMMSCs after albendazole administration significantly reduced the release of liver enzymes (p<0.05) indicating liver cellularity improvement. The ultrasonographic, macroscopic, and histopathological findings confirmed the biochemical results. Significant elevation in the levels of tumor necrosis factor (TNF)-α and interferon (INF)-γ with a decline in interleukin (IL)-4 was observed in the untreated model (p<0.05). However, albendazole treatment followed by BMMSCs therapy significantly lowered the release of TNF-α and INF-γ, associated with significant production of IL-4 and IL-10 (p<0.05). CONCLUSION: The final results indicated that the liver functions, histopathological findings, and immune parameters were aggravated after experimental T. vitulorum infection. Albendazole treatment followed by BMMSCs therapy was found to assist in regeneration of injured hepatic tissue. Besides, it appeared to modulate host defensive immune responses against T. vitulorum antigens. This work could define more clearly the events that manipulate the host immune, histopathological, and biochemical responses to minimize obstacles in using stem cell therapy in animal toxocariosis. Veterinary World 2021-02 2021-02-08 /pmc/articles/PMC7994112/ /pubmed/33776300 http://dx.doi.org/10.14202/vetworld.2021.347-363 Text en Copyright: © Abo-Aziza, et al. http://creativecommons.org/licenses/by/4.0 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Abo-Aziza, Faten A. M.
Zaki, Abdel Kader A.
Alajaji, Ahmed I.
Al barrak, Saleh M.
Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model
title Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model
title_full Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model
title_fullStr Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model
title_full_unstemmed Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model
title_short Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model
title_sort bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing toxocara vitulorum-rat model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994112/
https://www.ncbi.nlm.nih.gov/pubmed/33776300
http://dx.doi.org/10.14202/vetworld.2021.347-363
work_keys_str_mv AT aboazizafatenam bonemarrowmesenchymalstemcellcoadjuvanttherapywithalbendazoleformanagingtoxocaravitulorumratmodel
AT zakiabdelkadera bonemarrowmesenchymalstemcellcoadjuvanttherapywithalbendazoleformanagingtoxocaravitulorumratmodel
AT alajajiahmedi bonemarrowmesenchymalstemcellcoadjuvanttherapywithalbendazoleformanagingtoxocaravitulorumratmodel
AT albarraksalehm bonemarrowmesenchymalstemcellcoadjuvanttherapywithalbendazoleformanagingtoxocaravitulorumratmodel